Belite Bio (BLTE) CMO-affiliated entity sells 10,000 ADS, retains 32,946

Rhea-AI Filing Summary

Belite Bio’s Chief Medical Officer, through affiliated entity Bioptima Ltd., reported net open-market sales of 10,000 American depositary shares (ADS) of BLTE on June 16. Each ADS represents one ordinary share. The sales occurred in multiple trades at prices ranging roughly from $137.19 to $145.60, based on weighted-average price disclosures. After these transactions, indirect holdings reported by Bioptima Ltd. stand at 32,946 ADS, indicating the CMO remains a significant indirect holder.

Insights

Equity ownership analyst

CMO-linked entity sells 10,000 BLTE ADS but keeps large stake.

The filing shows Bioptima Ltd., an entity associated with Belite Bio’s Chief Medical Officer, executed open-market sales totaling 10,000 ADS on June 16. All transactions involved non-derivative American depositary shares, with no option exercises or conversions reported.

Trade prices span weighted-average ranges from about $137.19 to $145.60, suggesting execution across several price levels during the day. The absence of derivative activity or tax-withholding codes indicates straightforward discretionary selling rather than mechanical vesting-related events.

Post-transaction indirect holdings reported for Bioptima Ltd. are 32,946 ADS, so the sales represent only a portion of the visible position. This pattern typically reads as a routine liquidity event, with overall impact on Belite Bio’s ownership structure appearing limited based on this single Form 4.

Insider Trade Summary

Net Seller: 10,000 shares ($1,405,729)

Net Sell 8 txns

Insider Scholl Hendrik Peter

Role Chief Medical Officer

Sold 10,000 shs ($1.41M)

Type	Security	Shares	Price	Value
Sale	American depositary share	2,054	$137.6053	$283K
Sale	American depositary share	784	$138.1767	$108K
Sale	American depositary share	3,140	$139.5734	$438K
Sale	American depositary share	540	$140.5828	$76K
Sale	American depositary share	100	$141.83	$14K
Sale	American depositary share	450	$142.1958	$64K
Sale	American depositary share	1,897	$143.55	$272K
Sale	American depositary share	1,035	$145.0212	$150K

Holdings After Transaction: American depositary share — 32,946 shares (Indirect, By Bioptima Ltd.)

Footnotes (1)

1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer. Represents the weighted average price of shares sold at prices that ranged from $137.19 to $137.9. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $138 to $138.74. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $139.01 to $139.9575. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $140.325 to $140.825. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $142.14 to $142.24. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $143.035 to $143.915. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $145.02 to $145.6. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

Key Figures

ADS sold: 10,000 ADS Lowest weighted-average sale price range: $137.19–$137.90 Highest weighted-average sale price range: $145.02–$145.60 +3 more

6 metrics

ADS sold 10,000 ADS Total open-market sales on June 16

Lowest weighted-average sale price range $137.19–$137.90 Footnote F2 price range for part of sales

Highest weighted-average sale price range $145.02–$145.60 Footnote F8 price range for part of sales

Single trade block 3,140 ADS at $139.5734 One open-market sale transaction on June 16

Post-transaction indirect holdings 32,946 ADS Indirectly held by Bioptima Ltd. after sales

Par value per ordinary share US$0.0001 per share Each ADS represents one ordinary share

Key Terms

American depositary share, weighted average price, open-market sale, indirect ownership, +1 more

5 terms

American depositary share financial

"Each American depositary share represents one ordinary share, par value US$0.0001 per share"

An American Depositary Share (ADS) is a U.S.-listed certificate that represents a specified number of shares in a foreign company, held by a custodian bank; it works like a receipt that allows U.S. investors to buy and trade foreign equity on American exchanges without dealing with another country’s markets. Investors care because ADSs make foreign stocks easier to access, improve liquidity and settlement in dollars, and can affect dividend payments, voting rights and regulatory oversight compared with buying the underlying foreign shares directly.

weighted average price financial

"Represents the weighted average price of shares sold at prices that ranged from $137.19 to $137.9"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

indirect ownership financial

""direct_or_indirect": "I", "nature_of_ownership": "By Bioptima Ltd.""

ordinary share financial

"represents one ordinary share, par value US$0.0001 per share, of the issuer"

An ordinary share is a unit of ownership in a company that gives the holder a stake in its profits and usually the right to vote on key decisions. Think of it like a slice of a pizza where each slice entitles you to a portion of what’s left after bills are paid; value can rise or fall with the business and may pay dividends, so it matters to investors for income, growth and control.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Scholl Hendrik Peter

(Last) (First) (Middle)

GOTTHARDSTRASSE 26

(Street)

ZUG SWITZERLAND 6300

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
BELITE BIO, INC [ BLTE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
American depositary share(1)	06/16/2026		S		2,054	D	$137.6053(2)	32,946	I	By Bioptima Ltd.
American depositary share(1)	06/16/2026		S		784	D	$138.1767(3)	32,162	I	By Bioptima Ltd.
American depositary share(1)	06/16/2026		S		3,140	D	$139.5734(4)	29,022	I	By Bioptima Ltd.
American depositary share(1)	06/16/2026		S		540	D	$140.5828(5)	28,482	I	By Bioptima Ltd.
American depositary share(1)	06/16/2026		S		100	D	$141.83	28,382	I	By Bioptima Ltd.
American depositary share(1)	06/16/2026		S		450	D	$142.1958(6)	27,932	I	By Bioptima Ltd.
American depositary share(1)	06/16/2026		S		1,897	D	$143.55(7)	26,035	I	By Bioptima Ltd.
American depositary share(1)	06/16/2026		S		1,035	D	$145.0212(8)	25,000	I	By Bioptima Ltd.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer.

2. Represents the weighted average price of shares sold at prices that ranged from $137.19 to $137.9. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

3. Represents the weighted average price of shares sold at prices that ranged from $138 to $138.74. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

4. Represents the weighted average price of shares sold at prices that ranged from $139.01 to $139.9575. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

5. Represents the weighted average price of shares sold at prices that ranged from $140.325 to $140.825. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

6. Represents the weighted average price of shares sold at prices that ranged from $142.14 to $142.24. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

7. Represents the weighted average price of shares sold at prices that ranged from $143.035 to $143.915. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

8. Represents the weighted average price of shares sold at prices that ranged from $145.02 to $145.6. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

	/s/ Hendrik Peter Scholl	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Belite Bio (BLTE) report on this Form 4?

The Form 4 reports that Bioptima Ltd., an entity associated with Belite Bio’s Chief Medical Officer, sold 10,000 American depositary shares in open-market trades on June 16. All sales involved non-derivative ADS representing ordinary shares of BLTE.

Who executed the BLTE share sales disclosed in this Form 4?

The sales were executed by Bioptima Ltd., identified as holding the shares indirectly for Belite Bio’s Chief Medical Officer, Hendrik Peter Scholl. The filing attributes ownership to Bioptima Ltd. rather than to the executive personally.

How many Belite Bio (BLTE) shares were sold and at what prices?

The Form 4 shows aggregate sales of 10,000 American depositary shares. Individual trades occurred at weighted-average prices roughly between $137.19 and $145.60, reflecting multiple executions across a trading range on June 16.

What does each Belite Bio (BLTE) American depositary share represent?

Each American depositary share disclosed in the Form 4 represents one ordinary share of Belite Bio, with a par value of US$0.0001 per share. ADSs allow U.S. investors to hold and trade interests in the company’s ordinary shares.

How many Belite Bio (BLTE) shares does Bioptima Ltd. hold after the sales?

After completing the 10,000-ADS sale, the Form 4 reports that Bioptima Ltd. holds 32,946 American depositary shares indirectly. This remaining position indicates the entity continues to own a substantial block of BLTE shares following the transactions.

Were the Belite Bio (BLTE) insider transactions part of any option exercise?

No. The transactions listed on this Form 4 are all coded as non-derivative open-market sales of American depositary shares. There are no option exercises, conversions, or other derivative transactions reported in the derivative section.